Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections

Sotrovimab, an antibody active against severe acute respiratory syndrome coronavirus 2 that neutralizes antibodies, reduced the risk of COVID-19-related hospitalization or death in studies conducted before the emergence of the Omicron variant. The objective of this study is to evaluate the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyashita, Naoyuki, Nakamori, Yasushi, Ogata, Makoto, Fukuda, Naoki, Yamura, Akihisa, Ishiura, Yoshihisa, Ito, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302949/
https://www.ncbi.nlm.nih.gov/pubmed/37376600
http://dx.doi.org/10.3390/v15061300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302949/
https://www.ncbi.nlm.nih.gov/pubmed/37376600
http://dx.doi.org/10.3390/v15061300

Ejemplares similares